ABIVAX press release
ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States.
The protocols for the phase 3 induction studies of obefazimod in the treatment of ulcerative colitis (UC) have been approved by the American central ethics committee (IRB – Institutional Review Board).
The implementation of the phase 3 program is progressing as planned and the enrollment of a first patient in the United States is expected by the end of the third quarter of 2022.
The first submissions of phase 3 protocols to European regulatory agencies are scheduled for August 2022.